Ethics declarations Ethics Approval and Consent to Participate No human subjects were involved in this study
#neuropathy #nervepain #neurology #medicaleducation #healthcareprofessionals #nurses #doctors #pharmacists #paramedics #medicalstudents #diabeticneuropathy #chronicpain To view or add a comment, sign in Smart Research Review: A randomized clinical trial and subgroup analysis to compare flexion-distraction with active exercise for chronic low back pain ...subjects randomly allocated to the flexion-distraction group had significantly greater relief from pain than those allocated to the exercise program. ...subjects categorized as chronic, with moderate to severe symptoms, improved most with the flexion-distraction protocol. ...a greater decrease in VAS among patients with radiculopathy should be expected for the flexion-distraction group where changes in disc pressure may be most important. To view or add a comment, sign in Breaking: New 2025 AHA/ACC Hypertension Guidelines The American Heart Association (AHA) and American College of Cardiology (ACC) along with global partners have released the updated 2025 High Blood Pressure Guidelines, replacing the 2017 version
& LaFerla, F
MedicalMex facilitates: Prescription verification and fulfillment coordination Secure, compliant medication logistics Access to licensed Canadian pharmacists Access to our network of certified physicians if a Telehealth consultation is needed Case management, payment handling, and personalized boutique-level support Cold chain shipping with next-generation temperature-monitored coolers, when required Refill tracking and patient adherence programs You are working directly with MedicalMex Inc., a U.S.-based company that helps eligible patients safely access affordable medications from Canada with compliance and full-service concierge support at every step
Any residual soreness in the flank or lower abdomen should fade noticeably
Both the American Diabetes Association (ADA) and the European Society of Cardiology (ESC) now advocate for GLP-1 receptor agonists in patients with atherosclerotic cardiovascular disease, regardless of their initial HbA1c levels
